Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gilles Lambert

Showing results (11-20 of 164) with videos related to

Pageof 17
Sort By:
European Heart Journal. Case Reports|April 26, 2019
Recurrent coronary syndromes in a patient with isolated very-high lipoprotein (a) and the prothrombin genetic variant rs1799963 (G20210A): a case reportIlya Khantalin, Valentin Blanchard, Nicolas Viallet, et al.
Clinical Biochemistry|April 1, 2014
Plasma proprotein convertase subtilisin-kexin type 9 is predominantly related to intermediate density lipoproteinsArjan J Kwakernaak, Gilles Lambert, Robin P F Dullaart
Soins. Gerontologie|March 8, 2003
[The quality charter of nurses' aides]Claude Serveaux, Gilles Lambert, Edwige Foucault, et al.
Clinical Biochemistry|July 20, 2012
Relationship of proprotein convertase subtilisin-kexin type 9 levels with resistin in lean and obese subjectsArjan J Kwakernaak, Gilles Lambert, Robin P F Dullaart
Current Atherosclerosis Reports|December 5, 2023
HDL as a Treatment Target: Should We Abandon This Idea?Floran Begue, Marie Laurine Apalama, Gilles Lambert, et al.
Nature Reviews. Endocrinology|October 28, 2018
Inhibiting PCSK9 - biology beyond LDL controlRobert M Stoekenbroek, Gilles Lambert, Bertrand Cariou, et al.
Medecine Sciences : M/S|August 27, 2004
[Intestinal cholesterol absorption and NPC1-L1]Gilles Lambert, Maud Chetiveaux, Gaylord Sénard, et al.
Atherosclerosis|May 23, 2022
Recent advances in demystifying the metabolism of lipoprotein(a)Kévin Chemello, Dick C Chan, Gilles Lambert, et al.
Atherosclerosis|July 25, 2008
Molecular basis of PCSK9 functionGilles Lambert, Francesca Charlton, Kerry-Anne Rye, et al.
Rheumatology (Oxford, England)|March 5, 2021
Comment on: Proprotein convertase subtilisin/kexin type 9 in the dyslipidaemia of patients with axial spondyloarthritis is related to disease activityMaaike Heslinga, Gilles Lambert, Aurélie Thédrez, et al.
Pageof 17

Showing results (11-20 of 164) with videos related to

Sort By:
Pageof 17
European Heart Journal. Case Reports|April 26, 2019
Recurrent coronary syndromes in a patient with isolated very-high lipoprotein (a) and the prothrombin genetic variant rs1799963 (G20210A): a case reportIlya Khantalin, Valentin Blanchard, Nicolas Viallet, et al.
Clinical Biochemistry|April 1, 2014
Plasma proprotein convertase subtilisin-kexin type 9 is predominantly related to intermediate density lipoproteinsArjan J Kwakernaak, Gilles Lambert, Robin P F Dullaart
Soins. Gerontologie|March 8, 2003
[The quality charter of nurses' aides]Claude Serveaux, Gilles Lambert, Edwige Foucault, et al.
Clinical Biochemistry|July 20, 2012
Relationship of proprotein convertase subtilisin-kexin type 9 levels with resistin in lean and obese subjectsArjan J Kwakernaak, Gilles Lambert, Robin P F Dullaart
Current Atherosclerosis Reports|December 5, 2023
HDL as a Treatment Target: Should We Abandon This Idea?Floran Begue, Marie Laurine Apalama, Gilles Lambert, et al.
Nature Reviews. Endocrinology|October 28, 2018
Inhibiting PCSK9 - biology beyond LDL controlRobert M Stoekenbroek, Gilles Lambert, Bertrand Cariou, et al.
Medecine Sciences : M/S|August 27, 2004
[Intestinal cholesterol absorption and NPC1-L1]Gilles Lambert, Maud Chetiveaux, Gaylord Sénard, et al.
Atherosclerosis|May 23, 2022
Recent advances in demystifying the metabolism of lipoprotein(a)Kévin Chemello, Dick C Chan, Gilles Lambert, et al.
Atherosclerosis|July 25, 2008
Molecular basis of PCSK9 functionGilles Lambert, Francesca Charlton, Kerry-Anne Rye, et al.
Rheumatology (Oxford, England)|March 5, 2021
Comment on: Proprotein convertase subtilisin/kexin type 9 in the dyslipidaemia of patients with axial spondyloarthritis is related to disease activityMaaike Heslinga, Gilles Lambert, Aurélie Thédrez, et al.
Pageof 17